Journal Home
Search for

Volume 4, Issue 2, Pages 126-132 (March 2010)


View previous. 10 of 13 View next.

Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients

JoAnne M. Foody, MD, FACC, FAHAaCorresponding Author Informationemail address, Shiva G. Sajjan, PhDb, X. Henry Hu, MD, PhDb, Dena R. Ramey, BAc, David R. Neff, DOc, Andrew M. Tershakovec, MD, MPHc, Joanne E. Tomassini, PhDc, Chuck Wentworth, BSc, Kaan Tunceli, PhDb

Received 28 January 2010; accepted 29 January 2010. published online 08 February 2010.

Background

Guidelines recommend a low-density lipoprotein cholesterol (LDL-C) measurement of <70 mg/dL as a reasonable goal in high-risk patients with coronary heart disease (CHD) or atherosclerotic vascular disease (AVD).

Methods

This retrospective, cross-sectional study examined LDL-C goal attainment monthly trends from January 1, 2004, to August 31, 2008, in a large, managed-care claims database in the United States. High-risk CHD or AVD patients who had at least one LDL-C test during that time period were included (N = 284,915). Average LDL-C values and percent of patients not achieving LDL-C goal (LDL-C ≥70 mg/dL) were obtained by averaging patient level LDL-C values for each month. A linear trend analysis with first-order autocorrelated errors was conducted.

Results

The proportion of patients treated with lipid-lowering therapy gradually increased from 58.5% in 2004 to 70.5% in 2008. Mean LDL-C values in patients treated with lipid-lowering therapy decreased from 100.4 to 96.4 mg/dL, whereas LDL-C remained relatively constant in untreated patients (114.3 mg/dL). In treated patients, the percentage with LDL-C ≥70 mg/dL decreased from 87.5% in January 2004 to 73.8% in December 2006 (P < .0001), then gradually declined between January 2007 (79.6%) and August 2008 (76.2%; P < .0001). Among untreated patients, 92.9% had LDL-C levels ≥70 mg/dL in January 2004 and 93.0% in August 2008.

Conclusion

In conclusion, the percentage of high-risk patients with CHD or AVD treated with lipid-lowering therapy who achieve LDL-C <70 mg/dL levels has increased since 2004, although a large proportion of these patients still do not meet this goal. Additionally, 1 of 4 high-risk patients otherwise eligible for lipid-lowering therapy remains untreated. These data suggest the need for renewed efforts to support guideline-based LDL-C lowering in high-risk patients.

a Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA

b Merck and Co, Inc., Whitehouse Station, NJ, USA

c Merck and Co, Inc., N. Wales, PA, USA

Corresponding Author InformationCorresponding Author:

PII: S1933-2874(10)00046-2

doi:10.1016/j.jacl.2010.01.007


View previous. 10 of 13 View next.